Akston Biosciences Corp

FWP supplemental

Akston Biosciences Corp. is conducting an IPO offering 2,222,222 shares of common stock at $8.00-$10.00 per share, targeting approximately $20M in proceeds. The company focuses on developing biologic therapies for companion animals, with product candidates in cancer, obesity, allergy, and pain. Key initiatives include completing a USDA manufacturing facility, initiating pivotal trials for AKS-701d, and advancing cell line development. The offering is underwritten by ThinkEquity.

S-1/A amended

Range $8.00 to $10.00 · 2,222,222 shares

Akston Biosciences Corp, a pet biotechnology company, is conducting an IPO to commercialize biopharmaceutical products for companion animals. The offering includes 2,222,222 shares of common stock at an estimated price range of $8.00-$10.00. The company focuses on developing innovative therapies for pets, including AKS-701d for canine bladder cancer, leveraging its Ambifect® Fc-fusion protein platform. The IPO proceeds will fund manufacturing, clinical trials, and regulatory initiatives. The company anticipates conditional approval for AKS-701d in 2027 and aims to establish itself in the growing pet health market.

FWP supplemental

Range $8.00 to $10.00 · 2,222,222 shares · Gross proceeds $20,000,000

Akston Biosciences Corp, a biotech company focused on developing veterinary biologics for companion animals, is conducting an IPO to raise approximately $20 million. The offering includes 2,222,222 shares of common stock at a price range of $8.00-$10.00. The company aims to advance its clinical-stage product candidates, including AKS-701d for canine bladder cancer and AKS-548d for osteoarthritis, while expanding its manufacturing capabilities and regulatory approvals. The filing emphasizes its proprietary Fc-fusion protein platform and strategic partnerships with institutions like Purdue University.

S-1/A amended

Range $8.00 to $10.00 · 2,222,222 shares

Akston Biosciences Corp. is conducting an initial public offering (IPO) of 2,222,222 shares of common stock at an estimated price range of $8.00 to $10.00 per share. The company, a pet biotechnology firm, focuses on developing biopharmaceutical products for companion animals, with a lead candidate, AKS-701d, targeting urothelial carcinoma in dogs. The offering aims to fund clinical trials, manufacturing, and regulatory efforts, with anticipated conditional approval of AKS-701d in 2027. The company emphasizes its proprietary Ambifect® platform, designed to reduce dosing frequency and costs for monoclonal antibody therapies.

FWP supplemental

Range $8.00 to $10.00 · 2,222,222 shares · Gross proceeds $20,000,000

Akston Biosciences Corp. is a biotechnology company focused on developing veterinary therapeutics for pets, with a pipeline targeting cancer, obesity, allergy, and chronic pain. The company is conducting an IPO offering 2,222,222 shares of common stock at $8.00-$10.00 per share, aiming to raise ~$20M. Proceeds will fund facility renovation, clinical trials, regulatory submissions, and product development. The company leverages a proprietary Fc-fusion protein platform and has preclinical and clinical-stage candidates like AKS-701d for canine bladder cancer and AKS-548d for osteoarthritis. The offering is underwritten by ThinkEquity.

S-1/A amended

Range $8.00 to $10.00 · 2,222,222 shares

Akston Biosciences Corp. is conducting an IPO to raise capital for its pet biotechnology initiatives, offering 2,222,222 shares of common stock at an estimated price range of $8.00-$10.00. The company focuses on developing biopharmaceutical products for companion animals, leveraging its Ambifect® Fc-fusion protein platform to address conditions like cancer, dermatitis, and obesity. The IPO follows amendments to its registration statement, with proceeds intended for facility development, clinical trials, and product commercialization. The company aims to list on the NYSE American under the symbol "AXTN."

FWP supplemental

Range $8.00 to $10.00 · 2,222,222 shares · Gross proceeds $20,000,000

Akston Biosciences Corp, a biotechnology company focused on developing therapeutic products for companion animals, is conducting an initial public offering (IPO) of 2,222,222 shares of common stock at an estimated price range of $8.00 to $10.00 per share. The company aims to raise $20 million to advance its clinical-stage product candidates, including AKS-701d for canine bladder cancer, AKS-548d for osteoarthritis, and AKS-619d for chronic pain. The offering includes plans for facility expansion, pivotal trials, and regulatory approvals. The company's platform leverages Fc-fusion proteins and aims to capitalize on the growing companion animal health market, which is projected to exceed $152 billion in the U.S. in 2024.

S-1/A amended

Range $8.00 to $10.00 · 2,222,222 shares · Gross proceeds $22,222,220

Akston Biosciences Corp is conducting a firm commitment initial public offering of 2,222,222 shares of common stock, with an estimated price range of $8.00 to $10.00 per share. The company develops biopharmaceutical products for companion animals, focusing on innovative therapies for conditions like urothelial carcinoma and atopic dermatitis. Its lead product candidate, AKS-701d, targets PD-L1 and has received conditional eligibility for a license from the USDA. The offering is contingent on NYSE American listing, with underwriters including ThinkEquity. The company is an emerging growth company with reduced reporting requirements.

S-1/A amended

Range $8.00 to $10.00 · 2,222,222 shares

Akston Biosciences Corp. is conducting an IPO to raise capital for its development of biopharmaceutical products targeting companion animals. The company's Ambifect® platform aims to improve monoclonal antibody therapies for conditions like cancer and arthritis in pets. The IPO offers 2,222,222 shares at an estimated price range of $8.00-$10.00, with plans to list on the NYSE American under 'AXTN'. The offering includes underwriting discounts, warrants, and a 45-day option for additional shares.

S-1/A amended

Range $8.00 to $10.00 · 2,222,222 shares

Akston Biosciences Corp, a pet biotechnology company, is conducting an initial public offering (IPO) of 2,222,222 shares of common stock at an estimated price range of $8.00 to $10.00 per share. The company focuses on developing biopharmaceutical products for companion animals, leveraging its proprietary Ambifect® platform to create innovative therapies for conditions like cancer, dermatitis, and arthritis. The IPO aims to fund clinical trials and commercialization efforts, with the company expecting to list on the NYSE American under the symbol "AXTN." Akston is an emerging growth company and smaller reporting company, electing reduced reporting requirements under U.S. securities laws.

S-1 filed

Range $8.00 to $10.00 · 2,222,222 shares

Akston Biosciences Corp, a pet biotechnology company, is conducting an IPO to raise capital for its biopharmaceutical product pipeline targeting companion animals. The company plans to offer 2,222,222 shares of common stock at an estimated price range of $8.00 to $10.00 per share, aiming to list on the NYSE American under the symbol "AXTN." The offering is underwritten by ThinkEquity. Akston's lead product candidate, AKS-701d, targets PD-L1 for canine bladder cancer, with potential approvals anticipated in 2027 and 2029 for additional candidates. The company emphasizes its proprietary Ambifect® platform to reduce dosing frequency and costs for monoclonal antibody therapies.

DRS/A amended

Akston Biosciences Corp. filed an amended registration statement (DRS/A) for its initial public offering (IPO), detailing a firm commitment offering of common stock. The company, focused on developing biopharmaceutical products for companion animals, utilizes its proprietary Ambifect® platform to address unmet medical needs in pets. The IPO aims to list on NYSE American under the symbol 'AXTN,' with an estimated share price range and underwriting details provided. The filing highlights risks related to clinical trial outcomes, regulatory approvals, and market competition.

DRS filed

Akston Biosciences Corp, a pet biotechnology company, is conducting a confidential IPO filing (DRS) for its common stock. The company focuses on developing biopharmaceutical products for companion animals, leveraging its proprietary Ambifect® platform to address serious conditions like cancer and chronic pain. The offering includes a lead candidate, AKS-701d, targeting PD-L1 for canine bladder cancer, with potential regulatory approval anticipated in 2025. The IPO is underwritten by ThinkEquity, with the company seeking to list on a stock exchange under the symbol "AXTN." Akston is an emerging growth company with risks tied to regulatory approvals, competition, and financial constraints.